Welcome!

News Feed Item

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

Summary

Cancer is the uncontrolled growth of abnormal cells in the body. It can affect numerous organs and tissues of the body. When a patient is suspected of having a particular type of cancer, a biopsy procedure is performed to extract a target tissue sample for histological analysis. This intervention typically provides a definitive cancer diagnosis for the patient. Given that these procedures play such an important role in the diagnostic pathway for various cancers, medical device manufacturers have worked to develop biopsy devices that maximize the volume and quality of the tissue samples, as well as decrease their negative impact on the patient's body. As seen with other medical device markets, less invasive biopsy techniques have entered the market and have established a new gold standard in many global regions.

While there are significant barriers facing this market, current and future players can still position themselves to obtain a competitive advantage. The major European countries included in this forecast have general mass screening programs for breast cancer detection and they will be increasing their adoption of more expensive VAB devices. Additionally, the emerging economies will see an increased shift from fine needle aspiration devices to more expensive core biopsy devices over the forecast.

Scope

- An overview of biopsy devices, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized EU biopsy devices market revenue and future forecasts from 2010 to 2012, forecast for 7 years to 2019.
- Investigation of current and future market competition for biopsy devices
- Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
- Competitor assessment including device approval analysis and device sales forecasts.
- Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
- Analysis of unmet needs within the market and opportunities for future players.
- Technology trends evaluation to assess strength of pipeline.
- An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
- Company profiles including business description, financial overview and SWOT analysis.
- Coverage of key market players.
- Strategic assessment of the biopsy devices sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL).

Reasons to buy

- Understand the trends shaping and driving EU biopsy devices Market.
- Realize device preferences of physicians who have performed the tests already.
- Access market sizing, forecasts and quantified growth opportunities in EU biopsy devices market through 2019.
- Quantify candidate patient populations to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
- Perform benchmarking analysis of growth opportunities against currently marketed products.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
- What's the next big thing in EU biopsy devices market landscape? Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Overview 14
2.2 Catalyst 15
2.3 Related Reports 15
3 Industry Overview 16
3.1 Types of Biopsies 16
3.1.1 Surgical Biopsy 16
3.1.2 Fine Needle Aspiration 16
3.1.3 Core Needle Biopsy 17
3.1.4 Vacuum-Assisted Biopsy 18
3.2 Biopsy Procedure Trends 18
3.2.1 EU 18
3.3 Market Access to Cancer Screening Programs 24
3.3.1 Regulation 24
3.3.2 Biopsy Device Adoption Patterns 27
3.3.3 Reimbursement Trends 31
3.4 Regulatory Issues/Recalls 33
3.5 Mergers & Acquisitions/Key Partnerships 34
3.5.1 Hologic Acquires Suros Surgical Systems 34
3.5.2 C. R. Bard Acquires SenoRx 34
3.5.3 Devicor Medical Products Acquires Breast Care Portfolio from Ethicon Endo-Surgery 34
3.6 Economic Impact of Cancer Screening and Treatment 35
3.7 Additional Indications for Biopsy Devices 36
4 Unmet Needs 37
4.1 Overview 37
4.2 More Efficient Screening Tests for Prostate Cancer 37
4.3 More Efficient Screening Tests for Breast Cancer 38
4.4 More Efficient Screening Guidelines for Thyroid Cancer 38
4.5 Screening Tests That Can Provide Histological Analysis In Situ 39
5 Market Opportunity Analysis 40
5.1 Increase Marketing for Vacuum-Assisted Biopsy Devices in European Countries 40
5.2 Bundling Solutions 41
5.3 Focus Efforts on China's Increasing Adoption of VAB Devices 42
5.4 Market for Prostate Cancer Screening Coverage in Europe 42
6 Market Drivers and Barriers 44
6.1 Market Drivers 44
6.1.1 Inadequate Screening Tests for Particular Cancers 44
6.1.2 Demand for Minimally-Invasive Biopsy Techniques 45
6.1.3 Increased Adherence to Certain Cancer Screening Guidelines 45
6.1.4 Aging Patient Population 46
6.2 Market Barriers 47
6.2.1 Increased Competition from Other Cancer Diagnostic Tests 47
6.2.2 Breast Biopsy Reimbursement Bundling 50
6.2.3 Decreased Adherence to Certain Cancer Screening Guidelines 52
6.2.4 Benefits of Mass Prostate Cancer Screening Being Outweighed by Risks 53
7 Competitive Assessment 55
7.1 Overview 55
7.2 Classification Based on System 55
7.2.1 Vacuum-Assisted Biopsy Devices 55
7.2.2 Core Needle Biopsy Devices 57
7.2.3 Fine Needle Aspiration Devices 58
8 Pipeline Assessment 60
8.1 Overview 60
8.1.1 Optical Biopsy 61
8.1.2 Liquid Biopsy 62
9 Clinical Trial Analysis 63
10 Current and Future Players 65
10.1 Trends in Corporate Strategy 65
10.2 Company Profiles 65
10.2.1 Argon Medical Devices 65
10.2.2 Boston Scientific 68
10.2.3 Cardinal Health 71
10.2.4 CareFusion Corporation 72
10.2.5 Cook Medical 74
10.2.6 C. R. Bard 77
10.2.7 Devicor Medical Products 83
10.2.8 DTR Medical 87
10.2.9 Gallini Medical Devices 88
10.2.10 Hologic 91
10.2.11 INRAD 94
10.2.12 Intact Medical Corporation 96
10.2.13 TSK Laboratory 98
11 Market Outlook 100
11.1 Company Market Share 100
11.1.1 Vacuum-Assisted Biopsy Market Share 100
11.1.2 Core Needle Biopsy/Fine Needle Aspiration Market Share 102
11.2 By Segment 103
11.2.1 Fine Needle Aspiration 103
11.2.2 Core Needle Biopsy 104
11.2.3 Vacuum-Assisted Biopsy 105
11.3 By Geography 106
11.3.1 France 106
11.3.2 Germany 107
11.3.3 Italy 109
11.3.4 Spain 110
11.3.5 United Kingdom 112
12 Appendix 114
12.1 Bibliography 114
12.2 Abbreviations 123
12.3 Report Methodology 125
12.3.1 Overview 125
12.3.2 Coverage 125
12.3.3 Primary Research 125
12.3.4 Secondary Research 126
12.3.5 Forecasting Methodology 127
12.4 Key Opinion Leaders Included in This Study 127
12.5 About the Authors 128
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 128
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 128
12.6 Global Head of Healthcare 129
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 129
12.7 About MediPoint 130
12.8 About GlobalData 130
12.9 Disclaimer 130

List of Tables

Table 1: Breast Cancer Incidence Rates, 5EU, 2010-2019 21
Table 2: Biopsy Device Adoption Patterns in Diagnosing Prostate Cancer, Global, 2013 and 2019 28
Table 3: Biopsy Device Adoption Patterns in Diagnosing Breast Cancer, Global, 2013 and 2019 29
Table 4: Biopsy Device Adoption Patterns in Diagnosing Lung Cancer, Global, 2013 and 2019 30
Table 5: Biopsy Device Adoption Patterns in Diagnosing Liver Cancer, Global, 2013 and 2019 30
Table 6: Biopsy Device Adoption Patterns in Diagnosing Thyroid Cancer, Global, 2013 and 2019 31
Table 7: Age Demographics, Age >65 Years, Global, 2013 46
Table 8: Stereotactic Breast Biopsy Ambulatory Surgery Center Billing, 2011 51
Table 9: Stereotactic Breast Biopsy Physician Billing, 2011 51
Table 10: Company Profile - Argon Medical Devices 66
Table 11: Product Portfolio - Argon Medical Devices 67
Table 12: Argon Medical Devices, SWOT Analysis, 2013 67
Table 13: Company Profile - Boston Scientific 68
Table 14: Product Portfolio - Boston Scientific 70
Table 15: Boston Scientific SWOT Analysis, 2013 70
Table 16: Company Profile - Cardinal Health 71
Table 17: Product Portfolio - Cardinal Health 72
Table 18: Cardinal Health SWOT Analysis, 2013 72
Table 19: Company Profile - CareFusion Corporation 73
Table 20: Product Portfolio - CareFusion 74
Table 21: CareFusion, SWOT Analysis, 2013 74
Table 22: Company Profile - Cook Medical 75
Table 23: Product Portfolio - Cook Medical 76
Table 24: Cook Medical, SWOT Analysis, 2013 77
Table 25: Company Profile - C. R. Bard 78
Table 26: Product Portfolio - C. R. Bard 78
Table 27: C.R. Bard, SWOT Analysis, 2013 82
Table 28: Company Profile - Devicor Medical Products 83
Table 29: Product Portfolio - Devicor Medical Products 86
Table 30: Devicor Medical Products SWOT Analysis, 2013 86
Table 31: Company Profile - DTR Medical 87
Table 32: Product Portfolio - DTR Medical 87
Table 33: DTR Medical SWOT Analysis, 2013 88
Table 34: Company Profile - Gallini Medical Devices 89
Table 35: Product Portfolio - Gallini Medical Devices 90
Table 36: Gallini Medical Devices SWOT Analysis, 2013 90
Table 37: Company Profile - Hologic 91
Table 38: Product Portfolio - Hologic 93
Table 39: Hologic SWOT Analysis, 2013 93
Table 40: Company Profile - INRAD 94
Table 41: Product Portfolio - INRAD 95
Table 42: INRAD SWOT Analysis, 2013 95
Table 43: Company Profile - Intact Medical Corporation 96
Table 44: Product Portfolio - Intact Medical Corporation 97
Table 45: Intact Medical Corporation SWOT Analysis, 2013 97
Table 46: Company Profile - TSK Laboratory 98
Table 47: Product Portfolio - TSK Laboratory 99
Table 48: TSK Laboratory SWOT Analysis, 2013 99
Table 49: VAB, Global Market Share, 2013 101
Table 50: CNB/FNA, Global Market Share, 2013 102
Table 51: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Table 52: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Table 53: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Table 54: France Biopsy Devices Sales ($m) Forecast, 2010-2019 106
Table 55: Germany Biopsy Devices Sales ($m) Forecast, 2010-2019 108
Table 56: Italy Biopsy Devices Sales ($m) Forecast, 2010-2019 109
Table 57: Spain Biopsy Devices Sales ($m) Forecast, 2010-2019 111
Table 58: United Kingdom Biopsy Devices Sales ($m) Forecast, 2010-2019 112

List of Figures

Figure 1: Biopsy Procedure Volumes: Prostate, 5EU, 2010-2019 19
Figure 2: Biopsy Procedure Volumes: Breast, 5EU, 2010-2019 20
Figure 3: Biopsy Procedure Volumes: Lung, 5EU, 2010-2019 22
Figure 4: Biopsy Procedure Volumes: Liver, 5EU, 2010-2019 23
Figure 5: Biopsy Procedure Volumes: Thyroid, 5EU, 2010-2019 24
Figure 6: EnCor Breast Biopsy System 79
Figure 7: EnCor Enspire Breast Biopsy System 80
Figure 8: EnCor Ultra Breast Biopsy System 80
Figure 9: Finesse Ultra Breast Biopsy System 81
Figure 10: Vacora Breast Biopsy System 82
Figure 11: Original Mammotome System 84
Figure 12: Mammotome Elite 85
Figure 13: Mammotome Revolve 86
Figure 14: VAB, Global Market Share, 2013 101
Figure 15: CNB/FNA, Global Market Share, 2013 102
Figure 16: EU FNA Device Sales ($m) Forecast, 2010-2019 103
Figure 17: EU CNB Device Sales ($m) Forecast, 2010-2019 104
Figure 18: EU VAB Device Sales ($m) Forecast, 2010-2019 105
Figure 19: France Biopsy Devices Sales ($) Forecast, 2010-2019 107
Figure 20: Germany Biopsy Devices Sales ($) Forecast, 2010-2019 108
Figure 21: Italy Biopsy Devices Sales ($) Forecast, 2010-2019 110
Figure 22: Spain Biopsy Devices Sales ($) Forecast, 2010-2019 111
Figure 23: United Kingdom Biopsy Devices Sales ($) Forecast, 2010-2019 113

Read the full report:
MediPoint: Biopsy Devices - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/diagnostics/medipoint_biopsy_devices_eu_analysis_market_forecasts.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Sometimes I write a blog just to formulate and organize a point of view, and I think it’s time that I pull together the bounty of excellent information about Machine Learning. This is a topic with which business leaders must become comfortable, especially tomorrow’s business leaders (tip for my next semester University of San Francisco business students!). Machine learning is a key capability that will help organizations drive optimization and monetization opportunities, and there have been some...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.